Roman R. Schimmer

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up.

Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up.

Journal: Research and practice in thrombosis and haemostasis

Published: December 05, 2025

The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.

The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.

Journal: Leukemia

Published: July 21, 2025

Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease.

Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease.

Journal: Blood

Published: June 06, 2025

Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germline ERCC6L2 disease.

Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germline ERCC6L2 disease.

Journal: Blood

Published: June 06, 2025

The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.

The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.

Journal: Cancer research

Published: April 05, 2024

Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab.

Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab.

Journal: British journal of haematology

Published: October 31, 2023

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.

Journal: EMBO molecular medicine

Published: March 27, 2023

Targeted Large-Volume Lymphocyte Removal Using Magnetic Nanoparticles in Blood Samples of Patients with Chronic Lymphocytic Leukemia: A Proof-of-Concept Study.

Targeted Large-Volume Lymphocyte Removal Using Magnetic Nanoparticles in Blood Samples of Patients with Chronic Lymphocytic Leukemia: A Proof-of-Concept Study.

Journal: International journal of molecular sciences

Published: February 14, 2023

Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells.

Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells.

Journal: JACC. CardioOncology

Published: May 10, 2022

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.

Journal: Blood advances

Published: August 02, 2021

MCL1 Is Required for Maintenance of Intestinal Homeostasis and Prevention of Carcinogenesis in Mice.

MCL1 Is Required for Maintenance of Intestinal Homeostasis and Prevention of Carcinogenesis in Mice.

Journal: Gastroenterology

Published: March 21, 2019

Hypoxia of the growing liver accelerates regeneration.

Hypoxia of the growing liver accelerates regeneration.

Journal: Surgery

Published: February 09, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026